Zomedica Secures CE Mark for TRUVIEWTM Digital Microscope & Telepathology System, Expanding Global Market Opportunities
Zomedica Corp. (NYSE American:ZOM) has secured CE Mark approval for its TRUVIEW™ digital microscopy and telepathology platform, enabling commercialization across the European Economic Area. The TRUVIEW system integrates advanced diagnostic features, including LiquiView™ liquid lens technology and TRUprep™ automated slide preparation, enhancing diagnostic accuracy and efficiency in veterinary care.
The platform optimizes workflow by providing high-quality slide preparation and enabling real-time remote consultation. This CE Mark certification affirms the system's compliance with EU health, safety, and environmental standards, marking a significant milestone for Zomedica's expansion into the European market.
Zomedica Corp. (NYSE American:ZOM) ha ottenuto l'
La piattaforma ottimizza il flusso di lavoro fornendo una preparazione dei vetrini di alta qualità e consentendo consultazioni remota in tempo reale. Questa certificazione CE conferma la conformità del sistema agli standard di salute, sicurezza e ambientali dell'UE, rappresentando un traguardo significativo per l'espansione di Zomedica nel mercato europeo.
Zomedica Corp. (NYSE American:ZOM) ha conseguido la aprobación CE para su plataforma de microscopía digital y telepatología TRUVIEW™, lo que permite su comercialización en el Espacio Económico Europeo. El sistema TRUVIEW integra características diagnósticas avanzadas, incluyendo la tecnología de lentes líquidas LiquiView™ y la preparación automatizada de portaobjetos TRUprep™, mejorando así la precisión y eficiencia diagnóstica en la atención veterinaria.
La plataforma optimiza el flujo de trabajo al ofrecer una preparación de portaobjetos de alta calidad y permitir consultas remotas en tiempo real. Esta certificación CE afirma la conformidad del sistema con los estándares de salud, seguridad y medio ambiente de la UE, marcando un hito significativo para la expansión de Zomedica en el mercado europeo.
Zomedica Corp. (NYSE American:ZOM)는 CE 마크 승인을 받았으며, 이는 TRUVIEW™ 디지털 현미경 및 원격 병리학 플랫폼의 상업화를 유럽 경제 지역에서 가능하게 합니다. TRUVIEW 시스템은 LiquiView™ 액체 렌즈 기술 및 TRUprep™ 자동 슬라이드 준비를 포함한 고급 진단 기능을 통합하여 수의학 진료의 진단 정확성과 효율성을 향상시킵니다.
이 플랫폼은 고품질 슬라이드 준비를 제공하고 실시간 원격 상담을 가능하게 하여 작업 흐름을 최적화합니다. 이 CE 마크 인증은 시스템이 EU의 건강, 안전 및 환경 기준을 준수함을 확인하며, Zomedica의 유럽 시장 확장에 있어 중요한 이정표가 됩니다.
Zomedica Corp. (NYSE American:ZOM) a obtenu l'
La plateforme optimise le flux de travail en offrant une préparation de lames de haute qualité et en permettant des consultations à distance en temps réel. Cette certification CE confirme la conformité du système aux normes de santé, de sécurité et d'environnement de l'UE, marquant une étape importante pour l'expansion de Zomedica sur le marché européen.
Zomedica Corp. (NYSE American:ZOM) hat die CE-Kennzeichnung für ihre TRUVIEW™-Plattform für digitale Mikroskopie und Telepathologie - genehmigt, die die Kommerzialisierung im Europäischen Wirtschaftsraum ermöglicht. Das TRUVIEW-System integriert fortschrittliche diagnostische Funktionen, einschließlich der LiquiView™-Flüssiglinsentechnologie und der TRUprep™-automatisierten Rutschenvorbereitung, was die diagnostische Genauigkeit und Effizienz in der Veterinärmedizin verbessert.
Die Plattform optimiert den Arbeitsablauf, indem sie eine hochwertige Rutschenvorbereitung bietet und Echtzeit-Fernberatungen ermöglicht. Diese CE-Kennzeichnung bestätigt die Konformität des Systems mit den Gesundheits-, Sicherheits- und Umweltstandards der EU und stellt einen wichtigen Meilenstein für die Expansion von Zomedica in den europäischen Markt dar.
- CE Mark approval allows Zomedica to commercialize TRUVIEW across the European Economic Area
- TRUVIEW platform integrates advanced diagnostic features, enhancing accuracy and efficiency
- Automated slide preparation saves valuable technician time
- Telepathology feature enables real-time remote consultation
- Expansion into European market opens new revenue opportunities
- None.
The CE Mark approval for Zomedica's TRUVIEW™ digital microscope is a significant development in veterinary diagnostics. This certification opens up a vast market opportunity in the European Economic Area, potentially boosting Zomedica's revenue streams. The TRUVIEW system's integration of advanced features like LiquiView™ and TRUprep™ addresses critical pain points in veterinary practices, namely diagnostic accuracy and operational efficiency.
From an investor's perspective, this approval could translate to increased market share and revenue growth in the medium to long term. However, it's important to monitor the adoption rate among European veterinary practices and any potential competitive responses from other players in the market. The telepathology feature, in particular, aligns with the growing trend of telemedicine in veterinary care, which could be a key differentiator for Zomedica.
The TRUVIEW™ system represents a paradigm shift in veterinary diagnostics. By automating slide preparation and integrating telepathology, it addresses two major challenges: consistency in sample preparation and access to specialist expertise. This could significantly improve diagnostic accuracy and reduce turnaround times for complex cases.
The system's potential to save technician time is particularly noteworthy in an industry facing staffing shortages. However, the success of this product will largely depend on its pricing strategy and ease of integration into existing veterinary workflows. Zomedica will need to provide robust training and support to ensure smooth adoption. If executed well, this could position Zomedica as a leader in veterinary diagnostic technology, potentially capturing a significant portion of the European market.
CE Mark approval opens European market for TRUVIEW system
ANN ARBOR, MI / ACCESSWIRE / September 5, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced it has secured the CE Mark for its revolutionary TRUVIEW™ digital microscopy and telepathology platform. The CE Mark certification affirms the system's compliance with the stringent health, safety, and environmental standards required by the European Union, enabling Zomedica to commercialize the TRUVIEW microscope across the European Economic Area (EEA).
The TRUVIEW platform integrates advanced diagnostic features, including LiquiView™ liquid lens technology for superior imaging and the proprietary TRUprep™ automated slide preparation system. This all-in-one solution empowers veterinary professionals with advanced capabilities that enhance both diagnostic accuracy and efficiency.
"The TRUVIEW microscope represents the latest leap in veterinary diagnostic technology," commented Bill Campbell, VP of Imaging at Zomedica. "By automating slide preparation and offering telepathology services, we are revolutionizing how veterinarians approach diagnostics, delivering unparalleled precision and operational efficiency."
Microscopic examination is a cornerstone of veterinary care, and the TRUVIEW system optimizes workflow by providing consistently high-quality slide preparation while saving valuable technician time. Additionally, the platform's telepathology feature enables real-time remote consultation, fostering collaboration among veterinary professionals and enhancing diagnostic confidence.
"Securing the CE Mark is a significant milestone for Zomedica," stated Larry Heaton, CEO of Zomedica. "Our TRUVIEW microscope's cutting-edge optics, automated slide preparation, and telepathology services set a new standard for veterinary diagnostics in Europe and throughout the world. We are excited to bring this transformative technology to veterinary practices across the EEA."
To learn more about the TRUVIEW digital microscope and its transformative capabilities, visit Zomedica's website at www.zomedica.com/truview.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on accesswire.com
FAQ
What is the significance of Zomedica (ZOM) obtaining CE Mark for TRUVIEW?
What are the key features of Zomedica's (ZOM) TRUVIEW system?
How does the TRUVIEW system benefit veterinary practices?
When did Zomedica (ZOM) announce the CE Mark approval for TRUVIEW?
